These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
410 related articles for article (PubMed ID: 20450175)
1. Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay. Jahnke W; Grotzfeld RM; Pellé X; Strauss A; Fendrich G; Cowan-Jacob SW; Cotesta S; Fabbro D; Furet P; Mestan J; Marzinzik AL J Am Chem Soc; 2010 May; 132(20):7043-8. PubMed ID: 20450175 [TBL] [Abstract][Full Text] [Related]
2. Direct binding assay for the detection of type IV allosteric inhibitors of Abl. Schneider R; Becker C; Simard JR; Getlik M; Bohlke N; Janning P; Rauh D J Am Chem Soc; 2012 Jun; 134(22):9138-41. PubMed ID: 22612329 [TBL] [Abstract][Full Text] [Related]
3. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors. Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644 [TBL] [Abstract][Full Text] [Related]
4. Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidate. Gray NS; Fabbro D Methods Enzymol; 2014; 548():173-88. PubMed ID: 25399646 [TBL] [Abstract][Full Text] [Related]
5. Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. Fabbro D; Manley PW; Jahnke W; Liebetanz J; Szyttenholm A; Fendrich G; Strauss A; Zhang J; Gray NS; Adrian F; Warmuth M; Pelle X; Grotzfeld R; Berst F; Marzinzik A; Cowan-Jacob SW; Furet P; Mestan J Biochim Biophys Acta; 2010 Mar; 1804(3):454-62. PubMed ID: 20152788 [TBL] [Abstract][Full Text] [Related]
6. Exploration of (S)-3-aminopyrrolidine as a potentially interesting scaffold for discovery of novel Abl and PI3K dual inhibitors. Zhang C; Tan C; Zu X; Zhai X; Liu F; Chu B; Ma X; Chen Y; Gong P; Jiang Y Eur J Med Chem; 2011 Apr; 46(4):1404-14. PubMed ID: 21295380 [TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl. Healy EF; Johnson S; Hauser CR; King PJ FEBS Lett; 2009 Sep; 583(17):2899-906. PubMed ID: 19660459 [TBL] [Abstract][Full Text] [Related]
9. Insight into the allosteric inhibition of Abl kinase. Fallacara AL; Tintori C; Radi M; Schenone S; Botta M J Chem Inf Model; 2014 May; 54(5):1325-38. PubMed ID: 24787133 [TBL] [Abstract][Full Text] [Related]
10. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Cowan-Jacob SW; Fendrich G; Manley PW; Jahnke W; Fabbro D; Liebetanz J; Meyer T Structure; 2005 Jun; 13(6):861-71. PubMed ID: 15939018 [TBL] [Abstract][Full Text] [Related]
11. Crystal structure of the abl-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions. Pisabarro MT; Serrano L; Wilmanns M J Mol Biol; 1998 Aug; 281(3):513-21. PubMed ID: 9698566 [TBL] [Abstract][Full Text] [Related]
12. Allosteric interactions between the myristate- and ATP-site of the Abl kinase. Iacob RE; Zhang J; Gray NS; Engen JR PLoS One; 2011 Jan; 6(1):e15929. PubMed ID: 21264348 [TBL] [Abstract][Full Text] [Related]
13. Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl. Hantschel O; Wiesner S; Güttler T; Mackereth CD; Rix LL; Mikes Z; Dehne J; Görlich D; Sattler M; Superti-Furga G Mol Cell; 2005 Aug; 19(4):461-73. PubMed ID: 16109371 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and docking study of 2-phenylaminopyrimidine Abl tyrosine kinase inhibitors. Lü S; Luo Q; Hao X; Li X; Ji L; Zheng W; Wang F Bioorg Med Chem Lett; 2011 Dec; 21(23):6964-8. PubMed ID: 22033461 [TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the T315I mutant of AbI kinase. Zhou T; Parillon L; Li F; Wang Y; Keats J; Lamore S; Xu Q; Shakespeare W; Dalgarno D; Zhu X Chem Biol Drug Des; 2007 Sep; 70(3):171-81. PubMed ID: 17718712 [TBL] [Abstract][Full Text] [Related]
16. Characterization of compound 584, an Abl kinase inhibitor with lasting effects. Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480 [TBL] [Abstract][Full Text] [Related]
17. Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site. Yang J; Campobasso N; Biju MP; Fisher K; Pan XQ; Cottom J; Galbraith S; Ho T; Zhang H; Hong X; Ward P; Hofmann G; Siegfried B; Zappacosta F; Washio Y; Cao P; Qu J; Bertrand S; Wang DY; Head MS; Li H; Moores S; Lai Z; Johanson K; Burton G; Erickson-Miller C; Simpson G; Tummino P; Copeland RA; Oliff A Chem Biol; 2011 Feb; 18(2):177-86. PubMed ID: 21338916 [TBL] [Abstract][Full Text] [Related]
18. 3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases. Thaimattam R; Daga PR; Banerjee R; Iqbal J Bioorg Med Chem; 2005 Aug; 13(15):4704-12. PubMed ID: 15914012 [TBL] [Abstract][Full Text] [Related]
19. Enhanced SH3/linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitors. Panjarian S; Iacob RE; Chen S; Wales TE; Engen JR; Smithgall TE J Biol Chem; 2013 Mar; 288(9):6116-29. PubMed ID: 23303187 [TBL] [Abstract][Full Text] [Related]
20. Rapid synthesis of Abelson tyrosine kinase inhibitors using click chemistry. Kalesh KA; Liu K; Yao SQ Org Biomol Chem; 2009 Dec; 7(24):5129-36. PubMed ID: 20024108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]